Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 14

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 14
---
 thereunder (which this proxy statement refers to as the “HSR Act”). A transaction notifiable under the HSR Act may not be completed until the expiration or termination of a
30-day waiting period following the parties’ filings of their HSR Act notification and report forms. If the Federal Trade Commission (which this proxy statement refers to as the “FTC”) or the
Antitrust Division of the Department of Justice (which this proxy statement refers to as the “DOJ”) issues a request for additional information and documentary materials (which this proxy statement refers to as a “Second
Request”) prior to the expiration of the initial waiting period, the parties must observe a second 30-day waiting period, which would begin to run only after the parties have substantially complied with
the Second Request, unless the waiting period is terminated earlier or the parties otherwise agree to extend the waiting period. The parties made the filings required under the HSR Act on August 29, 2025, and the initial 30-day waiting period will
expire at 11:59 p.m., Eastern Time, on September 29, 2025, unless otherwise terminated or extended.

In addition to clearance under
the HSR Act, the consummation of the Merger is also subject to the receipt of regulatory approvals in certain other jurisdictions, including antitrust approvals in China and Japan among others, as set forth in greater detail in the section of this
summary titled “—Conditions to the Closing of the Merger” and “The Merger Agreement—Conditions to the Closing of the Merger.”

The Merger cannot be completed until the parties obtain the necessary clearances or approvals to consummate the Merger or the applicable
waiting periods have expired or been terminated. There can be no assurance that all of the required regulatory approvals that might be required to consummate the Merger will be obtained and, if obtained, there can be no assurance as to the timing of
any such approvals, the parties’ ability to

-5-

obtain the approvals on satisfactory terms, or that such regulatory bodies or private parties will not seek to take legal action to enjoin the completion of the Merger, seek divestiture of substantial assets of the parties, or require the parties to license or hold separate assets or terminate existing relationships and contractual rights. Although Alcon and STAAR do not believe the Merger violates the antitrust or foreign investment laws in any jurisdiction, there can be no assurance that a challenge to the Merger on such grounds will not